Philip Morris International Announces Senior Global Communications Leadership Changes
19 Dezembro 2023 - 9:40AM
Business Wire
Moira Gilchrist named Chief Communications
Officer; Marian Salzman appointed SVP & Chief Corporate
Citizenship Officer
Philip Morris International Inc. (PMI) (NYSE: PM) today
announced senior management changes to further accelerate its rapid
transition to a substantially smoke-free company.
Effective January 1, 2024, Dr. Moira Gilchrist will be promoted
to Chief Communications Officer and join PMI’s Senior Management
Team. Moira has had a distinguished career at PMI since joining the
organization’s R&D function in 2006, serving most recently as
VP, Strategic and Scientific Communications. In her new position,
she will report to Chief Executive Officer Jacek Olczak.
Also effective January 1, 2024, Marian Salzman, currently SVP,
Global Communications, will assume the position of SVP & Chief
Corporate Citizenship Officer. After more than five years spent
building the Global Communications function, Marian will return to
the U.S. to serve as a driving force in developing PMI’s business
in the U.S. market.
“Moira has been an essential part of my team for more than five
years, and I am delighted that she will take over the reins of the
Global Communication function as I shift my focus to the U.S.
market,” said Marian Salzman. “She has been instrumental in shaping
the strategy of PMI’s Global Communications function as we evolve
the business and advance our smoke-free mission. I’m excited to see
all she will accomplish as she steps up to lead the function.”
“Over the past 17 years, Moira has demonstrated an outstanding
ability to build focused and high-performing teams, always seeking
fresh perspectives and insights to drive a culture of curiosity and
continuous improvement,” said CEO Jacek Olczak. “Coupled with her
superb communication skills, these attributes will serve the
company well as we pursue our ambitious goal of being a
substantially smoke-free company by 2030, with the aim of more than
two-thirds of our total net revenues coming from smoke-free
products.”
“It is a privilege to have been selected to take the baton from
Marian and lead our communications function globally,” said Moira
Gilchrist. “Marian has changed everything about how we communicate
as a company, and she has had a tremendous influence on me and the
extended team. We are a far stronger and more dynamic function
today, and I am excited to build on her achievements to continue to
move us forward.”
Since joining PMI in 2006, Moira has held several positions,
including leading the Reduced-Risk Products Corporate Affairs team,
serving as Director of Scientific Engagement within the R&D
function, and working in both product development and
commercialization. Prior to joining the company, Moira worked in
the pharmaceutical sector for more than a decade. She was a
principal consultant within PwC’s and IBM’s pharmaceutical industry
consulting groups and held positions within both industry and
nonprofit organizations as a developer of drug formulations. Moira
holds a degree in Pharmacy and a PhD in Pharmaceutical Sciences,
both from the University of Strathclyde in Glasgow, Scotland.
Forward-Looking and Cautionary Statements
This press release contains projections of future results and
goals and other forward-looking statements, including statements
regarding expected financial or operational performance; market
expectations; and business plans and strategies.
Achievement of future results is subject to risks, uncertainties
and inaccurate assumptions. In the event that risks or
uncertainties materialize, or underlying assumptions prove
inaccurate, actual results could vary materially from those
contained in such forward-looking statements. Pursuant to the “safe
harbor” provisions of the Private Securities Litigation Reform Act
of 1995, PMI is identifying important factors that, individually or
in the aggregate, could cause actual results and outcomes to differ
materially from those contained in any forward-looking statements
made by PMI.
PMI's business risks include: excise tax increases and
discriminatory tax structures; increasing marketing and regulatory
restrictions that could reduce our competitiveness, eliminate our
ability to communicate with adult consumers, or ban certain of our
products in certain markets or countries; health concerns relating
to the use of tobacco and other nicotine-containing products and
exposure to environmental tobacco smoke; litigation related to
tobacco use and intellectual property; intense competition; the
effects of global and individual country economic, regulatory and
political developments, natural disasters and conflicts; the impact
and consequences of Russia's invasion of Ukraine; changes in adult
smoker behavior; the impact of COVID-19 on PMI's business; lost
revenues as a result of counterfeiting, contraband and cross-border
purchases; governmental investigations; unfavorable currency
exchange rates and currency devaluations, and limitations on the
ability to repatriate funds; adverse changes in applicable
corporate tax laws; adverse changes in the cost, availability, and
quality of tobacco and other agricultural products and raw
materials, as well as components and materials for our electronic
devices; and the integrity of its information systems and
effectiveness of its data privacy policies. PMI's future
profitability may also be adversely affected should it be
unsuccessful in its attempts to produce and commercialize
reduced-risk products or if regulation or taxation do not
differentiate between such products and cigarettes; if it is unable
to successfully introduce new products, promote brand equity, enter
new markets or improve its margins through increased prices and
productivity gains; if it is unable to expand its brand portfolio
internally or through acquisitions and the development of strategic
business relationships; if it is unable to attract and retain the
best global talent, including women or diverse candidates; or if it
is unable to successfully integrate and realize the expected
benefits from recent transactions and acquisitions. Future results
are also subject to the lower predictability of our reduced-risk
product category's performance.
PMI is further subject to other risks detailed from time to time
in its publicly filed documents, including PMI’s Annual Report on
Form 10-K for the fourth quarter and year ended December 31, 2022
and Form 10-Q for the nine months ended and the quarter ended
September 30, 2023. PMI cautions that the foregoing list of
important factors is not a complete discussion of all potential
risks and uncertainties. PMI does not undertake to update any
forward-looking statement that it may make from time to time,
except in the normal course of its public disclosure
obligations.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international
tobacco company working to deliver a smoke-free future and evolving
its portfolio for the long term to include products outside of the
tobacco and nicotine sector. The company’s current product
portfolio primarily consists of cigarettes and smoke-free products.
Since 2008, PMI has invested more than USD 10.5 billion to develop,
scientifically substantiate and commercialize innovative smoke-free
products for adults who would otherwise continue to smoke, with the
goal of completely ending the sale of cigarettes. This includes the
building of world-class scientific assessment capabilities, notably
in the areas of pre-clinical systems toxicology, clinical and
behavioral research, as well as post-market studies. In November
2022, PMI acquired Swedish Match – a leader in oral nicotine
delivery – creating a global smoke-free champion led by the
companies’ IQOS and ZYN brands. The U.S. Food and Drug
Administration has authorized versions of PMI’s IQOS Platform 1
devices and consumables and Swedish Match’s General snus as
Modified Risk Tobacco Products. As of September 30, 2023, PMI's
smoke-free products were available for sale in 82 markets, and PMI
estimates that approximately 19.7 million adults around the world
had already switched to IQOS and stopped smoking. Smoke-free
products accounted for approximately 36.2% of PMI’s total
third-quarter 2023 net revenues. With a strong foundation and
significant expertise in life sciences, PMI announced in February
2021 its ambition to expand into wellness and healthcare areas and,
through its Vectura Fertin Pharma business, aims to enhance life
through the delivery of seamless health experiences. For more
information, please visit www.pmi.com and
www.pmiscience.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231219715965/en/
Philip Morris International David Fraser T. +41 (0)58 242
4500 E. David.Fraser@pmi.com
Philip Morris (NYSE:PM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Philip Morris (NYSE:PM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024